Ublituximab tested in adults with schizophrenia
Tests ublituximab in adults with schizophrenia, looking at symptom scores.
Plain-language title generated from the registry record
Registry title: Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
Key facts
- Where
- Little Rock and Richardson, United StatesSee the 2 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07680946, who can take part
Where in United States
- Little RockLittle Rock, United StatesTaking people
- RichardsonRichardson, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- TG Therapeutics, Inc.
- Trial code
- NCT07680946
- Record updated
- 30 October 2026
- Original description
The main objective of this Phase 2 study is to assess the efficacy of ublituximab as measured by Positive and Negative Syndrome Scale (PANSS) total score in participants with schizophrenia.Read full original descriptionShow less
Evaluating Safety and Efficacy of Ublituximab in Participants With Schizophrenia
The main objective of this Phase 2 study is to assess the efficacy of ublituximab as measured by Positive and Negative Syndrome Scale (PANSS) total score in participants with schizophrenia.
Inclusion: Primary diagnosis of schizophrenia; Treatment-resistant; Requires antipsychotic treatment and is currently receiving "standard of care"; PANSS total score between 80 and 120, inclusive at screening and baseline.
Exclusion: Any primary Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) disorder other than schizophrenia; Any severe or uncontrolled medical condition that could affect the participant's ability to participate; Note: Other protocol-specified Inclusion/Exclusion criteria may apply; Ongoing clozapine treatment; Risk for suicidal behavior.